TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of “Hold” by Brokerages

TScan Therapeutics, Inc. (NASDAQ:TCRX) has been assigned an average recommendation of “Hold” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $6.00.

Several research analysts recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and set a $6.00 price target on shares of TScan Therapeutics in a report on Tuesday, June 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen downgraded TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Finally, Wedbush reissued an “outperform” rating and issued a $5.00 price target on shares of TScan Therapeutics in a report on Tuesday, June 23rd.

Institutional Investors Weigh In On TScan Therapeutics

Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE grew its stake in shares of TScan Therapeutics by 48.7% during the 1st quarter. Bank of America Corp DE now owns 57,529 shares of the company’s stock worth $58,000 after purchasing an additional 18,829 shares during the period. Renaissance Technologies LLC lifted its stake in shares of TScan Therapeutics by 19.6% in the first quarter. Renaissance Technologies LLC now owns 1,364,783 shares of the company’s stock valued at $1,378,000 after purchasing an additional 223,714 shares during the period. Public Employees Retirement System of Ohio purchased a new stake in TScan Therapeutics during the first quarter worth about $28,000. Kestra Advisory Services LLC purchased a new stake in TScan Therapeutics during the first quarter worth about $63,000. Finally, XTX Topco Ltd grew its position in TScan Therapeutics by 1,142.5% during the fourth quarter. XTX Topco Ltd now owns 219,001 shares of the company’s stock worth $219,000 after buying an additional 201,375 shares during the period. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Stock Up 1.8%

Shares of TScan Therapeutics stock opened at $0.91 on Friday. TScan Therapeutics has a one year low of $0.83 and a one year high of $2.57. The company has a market cap of $59.78 million, a P/E ratio of -0.95 and a beta of 1.04. The company has a debt-to-equity ratio of 0.34, a quick ratio of 6.65 and a current ratio of 6.65. The firm has a fifty day moving average of $1.00 and a two-hundred day moving average of $1.06.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, meeting the consensus estimate of ($0.22). The business had revenue of $0.98 million for the quarter, compared to the consensus estimate of $2.50 million. TScan Therapeutics had a negative net margin of 1,360.61% and a negative return on equity of 91.94%. On average, analysts forecast that TScan Therapeutics will post -1.11 earnings per share for the current year.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.